- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05067075
The CGMS in GDM Labor and Delivery Study (CGMSGDMLABOR)
Role of Continuous Glucose Monitoring Systems (CGMS) for Intrapartum Metabolic Control in Gestational Diabetic (GDM)Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Planning management for a diabetic parturient during labor and delivery is particularly challenging because of the demands of labor, dietary restrictions, and potential for operative delivery. The main goals can be summarized as: ensuring the avoidance of maternal hypoglycemia or hyperglycemia (which can increase the risk of neonatal hypoglycemia), ensuring the safe use of measures to manage glycemic control, and the provision of effective analgesia for labor. Currently available international guidelines for the peripartum management of pregnant women with diabetes focus on rigorous intrapartum glycemic control. Maternal hyperglycemia in women with pregestational and gestational diabetes mellitus can cause hypoglycemia in the neonate following delivery. In women with diabetes, maternal hyperglycemia leads to hyperplasia of pancreatic β cells in the fetus and an increase in fetal insulin concentrations. When the continuous supply of glucose is stopped after delivery, the neonate is at risk of developing hypoglycemia, which if untreated can have serious neurological consequences. The increase in fetal insulin also contributes to the excess growth of the fetus in mothers with hyperglycemia. Avoiding intrapartum maternal hyperglycemia may prevent fetal hyperglycemia and reduce the likelihood of subsequent neonatal hypoglycemia. A further potential concern relates directly to the woman. Immediately after delivery, postpartum insulin requirements decrease dramatically as a result of the rapid decrease in diabetogenic placental hormone levels and resulting dissipation of pregnancy-induced insulin resistance. Pregnant women with diabetes may be at greater risk of hypoglycemic episodes because awareness of the symptoms of hypoglycemia is reduced, and this is further exacerbated by tight glycemic control .
Glucose control during labor is important for both fetus and mother. During labor and delivery, the goal is to maintain the sugars in the normal range as safely as possible as increased blood sugars 4-6 h prior to delivery leads to increased rates of hypoglycemia in the neonate. Neonatal hypoglycemia is a risk for the offspring of pregnant women with diabetes and occurs when fetal pancreatic hyperplasia is acutely stimulated by a high fetal glucose level derived from maternal hyperglycemia during labor. The maternal blood glucose level during delivery is a predictor of the neonatal blood glucose level, and a high blood glucose level in the mother is associated with neonatal hypoglycemia. Continuous glucose monitoring (CGM) use appears to be safe and effective in pregnancies complicated by diabetes. Modern CGM systems can capture the direction and magnitude of short-lived changes in interstitial glucose levels and are therefore useful for assessing glucose variability more accurately than self-monitoring blood glucose (SMBG) measurements. Indeed, it has already been demonstrated that intermittent blood glucose monitoring underestimates the number of hyperglycemic events because blood glucose excursions can peak at different times of day. CGMs can help identify glycemic patterns in pregnancy, obtain and maintain glucose targets, and reduce hypoglycemia. CGM helps with treatment adjustments in pregnancies associated with diabetes. Strict glycemic control during labor and delivery may reduce the risk of neonatal hypoglycemia. In principle, "real-time" CGM might allow more rapid adjustment of insulin dosing and, thereby, yield better glycemic control than is possible with intermittent glucose monitoring. Two groups have reported on the use of CGM during labor in small pilot studies. Stenninger et al. reported that CGM was well tolerated in their 15 subjects and that elevated maternal glucose levels in the last 2 hours before delivery correlated with the need for intravenous glucose in the newborn. They found that multiple glycemic indices correlated positively with the need for neonatal intravenous glucose infusions. Iafusco et al. used real-time CGM in 14 subjects to guide insulin therapy during labor and found no cases of neonatal hypoglycemia. Another study looked at effects of maternal glucose levels in insulin-treated women during labor and delivery (2 to 8 hours before birth) and resultant neonatal hypoglycemia. In the this study, 45% (27/60) of women in the CGM group were compared with 100% (59/59) in the control group. Among women in the CGM arm, 10 infants developed hypoglycemia compared with 27 in the non-CGM group (37% vs. 46%, respectively; P = 0.45). The researchers found that maternal hyperglycemia before delivery was correlated with neonatal hypoglycemia.
Although more studies are needed, CGM use has promise as a therapy to improve outcomes in pregnancies associated with diabetes. In this study, the investigators plan to explore whether the use of blinded glucose monitoring during labor, delivery, and early postpartum supplementary to normally monitored plasma glucose measurements in women with gestational diabetes (GDM) would provide useful information to improve glycemia during labor in this diabetic population.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Karen E Elkind-Hirsch, PhD
- Phone Number: 12252315278
- Email: karen.elkind-hirsch@womans.org
Study Contact Backup
- Name: Edward Veillon, MD
- Phone Number: 12252315392
- Email: edward.veillon@womans.org
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70815
- Woman's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- singleton pregnancy
- a positive oral glucose tolerance test
- written informed consent
- labor scheduled for term induction (37-40 weeks)
Exclusion Criteria:
- prior diagnosis of type 1 or type 2 diabetes mellitus
- presence of infection
- Presence of significant systemic disease or other severe metabolic, endocrine, or medical co-morbidities
- History of bariatric surgery or other surgeries that induce malabsorption
- Long-term use (>2 weeks) of systemic steroids prior to enrollment
- Multiple pregnancy
- Participants already using glucose lowering medications (metformin or insulin) for diabetes before study entry (can be used after diagnosis of GDM)
- Fetal growth restriction due to placental dysfunction or known congenital anomaly
- History of major depressive or other severe psychiatric disorders or inpatient psychiatric treatment up to 1 year before enrolment
- Inability or refusal to comply with protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Blinded CGM
Blinded continuous glucose monitor Dexcom G6Pro
|
CGM that records blood glucose but is not visible to patient or provider in real-time
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average percentage time in target glucose range
Time Frame: up to 10 days
|
average time in hours and minutes spent in target glucose range
|
up to 10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
average time spent in hyperglycemia (time above target range)
Time Frame: up to 10 days
|
average time in hours and minutes spent with elevated blood sugar
|
up to 10 days
|
average time spent in hypoglycemia (time below target range)
Time Frame: up to 10 days
|
average time in hours and minutes spent with low blood sugar
|
up to 10 days
|
neonatal hypoglycemia
Time Frame: up to 2 hours post delivery
|
Neonatal hypoglycemia is defined as a 2-hour plasma glucose value < 2.1 mmol/l (47 mg/dL taken 2 hours after delivery
|
up to 2 hours post delivery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
postpartum 2 hour 75 gram OGTT results from mother
Time Frame: from 6 to 12 weeks after delivery
|
glucose and insulin results from post delivery OGTT
|
from 6 to 12 weeks after delivery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Karen Elkind-Hirsch, PhD, Woman's Hospital, Louisiana
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP-21-017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes Mellitus in Pregnancy
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingGestational Diabetes Mellitus in PregnancyFrance
-
i-Health, Inc.CompletedGestational Diabetes Mellitus in PregnancyGermany
-
The Danish Center for Strategic Research on Type...Odense University HospitalCompletedGestational Diabetes Mellitus in PregnancyDenmark
-
Services Institute of Medical Sciences, PakistanCompletedGestational Diabetes Mellitus in PregnancyPakistan
-
Danone Asia Pacific Holdings Pte, Ltd.Nutricia ResearchTerminatedGestational Diabetes Mellitus in PregnancySingapore
-
Unity Health TorontoRecruitingGestational Diabetes Mellitus in PregnancyCanada
-
Women's Hospital School Of Medicine Zhejiang UniversityActive, not recruitingGestational Diabetes Mellitus in PregnancyChina
-
Peking Union Medical College HospitalUnknownGestational Diabetes Mellitus in PregnancyChina
-
Gulsum UysalCompletedGestational Diabetes Mellitus in PregnancyTurkey
-
Washington University School of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedGestational Diabetes | Gestational Diabetes Mellitus in PregnancyUnited States
Clinical Trials on Blinded CGM
-
University Hospital PadovaBoston Children's Hospital; University of PadovaCompletedInfant, Very Low Birth Weight | Neonatal HypoglycemiaUnited States, Italy
-
Jaeb Center for Health ResearchDexCom, Inc.Completed
-
University Hospital PadovaUniversity of PadovaRecruitingInfant Development | Neurodevelopmental Abnormality | Hypoglycemia NeonatalItaly
-
Woman'sDexCom, Inc.RecruitingPostpartum Gestational Diabetes MellitusUnited States
-
Emory UniversityDexCom, Inc.Recruiting
-
Palo Alto Medical FoundationEmory University; Abbott Diabetes CareRecruiting
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...RecruitingHyperglycemia StressUnited States
-
Lexicon PharmaceuticalsRecruitingDiabetic Peripheral Neuropathic PainUnited States
-
University of Ljubljana, Faculty of MedicineCompleted
-
AstraZenecaRecruitingSystemic Sclerosis | SclerodermaUnited Kingdom, United States, Italy, Mexico, Belgium, Germany, Spain, China, France, India, Austria, Canada, Poland, Israel, Korea, Republic of, Hungary, Japan, South Africa, Turkey, Netherlands, Romania